Analyse Ironwood Pharmaceuticals, Inc. (IRWD) — Kairos Score 69/100

À propos de Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Informations clés

🕴️ Activité des initiés (90 jours)

1 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Ironwood Pharmaceuticals, Inc..

🏦 Hedge Funds

18 fonds institutionnels déclarent une position sur IRWD dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur IRWD.

• Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
• Ironwood (IRWD) Q2 2026 Earnings Call Transcript

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.